Evidence map›Paper›PMID 38799446›Full record

ReviewFrontiers in immunology2024

Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis.

Yu Tian, Meng Zhang, Li-Xia Liu, Zi-Chao Wang, Bin Liu, Youcai Huang, Xiaoling Wang, Yun-Zhi Ling, Furong Wang, Xiaoqiang Feng and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. miR-184 in hepatocellular carcinoma: a promising therapeutic target.Journal of physiology and biochemistry · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. ST8SIA6-AS1, a novel lncRNA star in liver cancer.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu Tian *Research Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Meng Zhang *Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Li-Xia Liu *Department of Ultrasound, Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Zi-Chao WangDepartment of Ultrasound, Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Bin LiuCentral Laboratory, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Youcai HuangResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Xiaoling WangResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Yun-Zhi LingResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Furong WangDepartment of Pathology, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Xiaoqiang FengCenter of Stem Cell and Regenerative Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong, China.
Yanyang TuResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related deaths in the world. The development and progression of HCC are closely correlated with the abnormal regulation of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). Important biological pathways in cancer biology, such as cell proliferation, death, and metastasis, are impacted by these ncRNAs, which modulate gene expression. The abnormal expression of non-coding RNAs in HCC raises the possibility that they could be applied as new biomarkers for diagnosis, prognosis, and treatment targets. Furthermore, by controlling the expression of cancer-related genes, miRNAs can function as either tumor suppressors or oncogenes. On the other hand, lncRNAs play a role in the advancement of cancer by interacting with other molecules within the cell, which, in turn, affects processes such as chromatin remodeling, transcription, and post-transcriptional processes. The importance of ncRNA-driven regulatory systems in HCC is being highlighted by current research, which sheds light on tumor behavior and therapy response. This research highlights the great potential of ncRNAs to improve patient outcomes in this difficult disease landscape by augmenting the present methods of HCC care through the use of precision medicine approaches.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularGene Expression Regulation, NeoplasticLiver NeoplasmsAnimalsHumansMicroRNAsPrognosisRNA, Long NoncodingRNA, UntranslatedBiomarkers, TumorMicroRNAsRNA, Long NoncodingRNA, Untranslateddiagnosis and prognosisepigenetic factorshepatocellular carcinomamiRNA spongetherapy resistance

Identifiers

PMID38799446
PMCPMC11116607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.